SEC Form 4 · accession 0001214659-18-001759

Mirati Therapeutics, Inc. · MRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Jamie A Donadio

Officer — Sr. VP, CFO

Period of report

Mar 1, 2018

Accepted (ET)

Mar 2, 2018 · 6:08 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001576263

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 1, 2018	M	9,375	$5.50	A	9,375	D
Common Stock	Mar 1, 2018	M	12,500	$5.40	A	21,875	D
Common Stock	Mar 1, 2018	M	30,000	$7.30	A	51,875	D
Common Stock^F4	Mar 1, 2018	S	25,600	$26.7779	D	26,275	D
Common Stock^F5	Mar 1, 2018	S	25,775	$27.4526	D	500	D
Common Stock^F6	Mar 1, 2018	S	500	$28.08	D	0	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F2	$5.50	Mar 1, 2018	M	9,375	D	—	Oct 26, 2026	Common Stock	9,375	20,625	D
Employee Stock Option (Right to Buy)^F2	$5.40	Mar 1, 2018	M	12,500	D	—	Jan 25, 2027	Common Stock	12,500	37,500	D
Employee Stock Option (Right to Buy)^F3	$7.30	Mar 1, 2018	M	30,000	D	—	Mar 19, 2020	Common Stock	30,000	0	D

Explanation of responses

F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2017.
F21/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
F3Twenty percent (20%) of the shares subject to the stock option vested and became exercisable on the grant date of the option (March 20, 2013), and an additional 20% shall vest and become exercisable each year on the anniversary of the grant date.
F4This transaction was executed in multiple trades at prices ranging from $26.05 to $27.025. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5This transaction was executed in multiple trades at prices ranging from $27.05 to $28.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6This transaction was executed in multiple trades at prices ranging from $28.05 to $28.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.